- Home
- PCH vs VKTX Comparison
PCH vs VKTX Comparison
Compare PCH & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCH
- VKTX
- Stock Information
- Founded
- PCH 1903
- VKTX 2012
- Country
- PCH United States
- VKTX United States
- Employees
- PCH N/A
- VKTX N/A
- Industry
- PCH Real Estate Investment Trusts
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- PCH Real Estate
- VKTX Health Care
- Exchange
- PCH Nasdaq
- VKTX Nasdaq
- Market Cap
- PCH 3.0B
- VKTX 2.8B
- IPO Year
- PCH N/A
- VKTX 2015
- Fundamental
- Price
- PCH $40.58
- VKTX $31.11
- Analyst Decision
- PCH Strong Buy
- VKTX Buy
- Analyst Count
- PCH 7
- VKTX 12
- Target Price
- PCH $48.71
- VKTX $84.00
- AVG Volume (30 Days)
- PCH 568.0K
- VKTX 4.1M
- Earning Date
- PCH 07-28-2025
- VKTX 07-23-2025
- Dividend Yield
- PCH 4.43%
- VKTX N/A
- EPS Growth
- PCH 7.03
- VKTX N/A
- EPS
- PCH 0.61
- VKTX N/A
- Revenue
- PCH $1,102,209,000.00
- VKTX N/A
- Revenue This Year
- PCH $2.63
- VKTX N/A
- Revenue Next Year
- PCH $4.86
- VKTX N/A
- P/E Ratio
- PCH $66.88
- VKTX N/A
- Revenue Growth
- PCH 10.86
- VKTX N/A
- 52 Week Low
- PCH $36.82
- VKTX $18.92
- 52 Week High
- PCH $48.12
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- PCH 57.33
- VKTX 64.49
- Support Level
- PCH $39.27
- VKTX $29.76
- Resistance Level
- PCH $41.08
- VKTX $31.57
- Average True Range (ATR)
- PCH 1.00
- VKTX 1.79
- MACD
- PCH 0.18
- VKTX 0.50
- Stochastic Oscillator
- PCH 84.18
- VKTX 94.08
About PCH PotlatchDeltic Corporation
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.